What is the appropriate dose of trimethoprim‑sulfamethoxazole (Septra DS) for a 49‑kg child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dosing Septra DS for a 49 kg Child

For a 49 kg child, the appropriate dose of trimethoprim-sulfamethoxazole (Septra DS) depends on the indication, but for most common infections, give 8-12 mg/kg/day of the trimethoprim component divided into two doses every 12 hours, which translates to approximately 1-1.5 DS tablets twice daily.

Indication-Specific Dosing

For Skin and Soft Tissue Infections (SSTI)

For purulent cellulitis or MRSA coverage, administer 8-12 mg/kg/day based on the trimethoprim component in 2 divided doses 1. For a 49 kg child:

  • Trimethoprim component: 392-588 mg/day total
  • This equals approximately 1 DS tablet (160 mg TMP/800 mg SMX) twice daily for the lower end, or 1.5 DS tablets twice daily for higher dosing
  • Duration: typically 5-10 days depending on clinical response

For Urinary Tract Infections or Acute Otitis Media

The FDA-approved dosing is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, divided every 12 hours for 10 days 2. For a 49 kg child:

  • This calculates to 1 DS tablet twice daily (each DS tablet contains 160 mg TMP/800 mg SMX)
  • Duration: 10 days for UTI, 5 days for shigellosis

For Pneumocystis Pneumonia (PCP)

Treatment dosing: 15-20 mg/kg/day of trimethoprim component (75-100 mg/kg/day of sulfamethoxazole) divided every 6 hours for 14-21 days 3, 2. For a 49 kg child:

  • This equals 2-2.5 DS tablets every 6 hours (approximately 8-10 DS tablets per day total)
  • This is substantially higher than prophylactic dosing

Prophylaxis dosing: 150 mg/m²/day trimethoprim with 750 mg/m²/day sulfamethoxazole, given in 2 divided doses, 3 consecutive days per week 4. The total daily dose should not exceed 320 mg trimethoprim and 1600 mg sulfamethoxazole (2 DS tablets) 2.

Important Clinical Considerations

Age-Related Pharmacokinetics

Children have higher clearance and shorter half-lives of TMP-SMX compared to adults 5. Research demonstrates that children aged 8-10 years have a mean elimination half-life of 5.4 hours versus 11.2 hours in adults, with higher total clearance (2.4 ml/min/kg vs 1.4 ml/min/kg) 5. This supports the need for weight-based dosing rather than simply using adult tablets.

Monitoring Requirements

  • Complete blood counts should be performed at initiation and monthly intervals to assess for hematologic toxicity (neutropenia, thrombocytopenia, anemia) 6
  • Monitor renal function, particularly with prolonged therapy
  • Watch for hyperkalaemia, which occurs in 27.4% of patients on high-dose therapy 7

Common Pitfalls to Avoid

  1. Do not use in children under 2 months of age 2
  2. Septra DS tablets are "double strength" - each contains 160 mg TMP/800 mg SMX. Regular strength tablets contain 80 mg TMP/400 mg SMX. Ensure you're prescribing the correct formulation
  3. For severe infections requiring IV therapy, dosing differs significantly and should be calculated separately
  4. Adjust dosing in renal impairment: For creatinine clearance 15-30 mL/min, give half the usual dose; avoid use if CrCl <15 mL/min 2

Adverse Effects

The most common adverse reaction is rash, occurring at nearly 3-fold higher rates compared to other antibiotics 8. Serious reactions include Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), and hematologic abnormalities 3. If urticarial rash or Stevens-Johnson syndrome occurs, discontinue immediately and do not rechallenge 3.

References

Research

Comparative effectiveness of trimethoprim-sulfamethoxazole dosing strategies for Pneumocystis jirovecii pneumonia: a target trial emulation.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2026

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.